Grants and Contributions:
Title:
COVID-19 Rapid Response: Novel Immune Therapeutic for the Prevention and Treatment of COVID-19
Agreement Number:
955668
Agreement Value:
$38,170.00
Agreement Date:
Aug 17, 2020 - Mar 31, 2021
Description:
Develop processes and methods for quality control analytics and aseptic reagent and product handling, in preparation for commercial scale lot production of QBKPN, the Firm's lung-specific Site Specific Immunomodulator (SSI), for use in a planned clinical trial for COVID-19 prevention.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Burnaby, British Columbia, CA V5G 4X4
Reference Number:
172-2020-2021-Q2-955668
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
842333817
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 2 time(s). The end date of this agreements has been modified by 59 days. The total amended value is -311,830 dollars.
Amendment Date
Feb 22, 2021
Recipient's Legal Name:
Qu Biologics Inc.
Federal Riding Name:
Burnaby South
Federal Riding Number:
59003
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710
Amendments: